FDA Declines Clearance of Nanosphere PMA for Plavix Metabolism Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere today said that it has received a not approvable letter from the US Food and Drug Administration for its Verigene Clopidogrel Metabolism Nucleic Acid Test.

Shares of Nanosphere dropped 24 percent to $1.69 in early Tuesday trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.